INTRODUCTION
Cardiac catheterization is one of the basic methods applied in the diagnosis and treatment of congenital and acquired cardiovascular diseases during childhood 1 . However, the fact that cardiac catheterization is an invasive procedure that requires anesthesia encourages clinicians to use non-invasive methods 2 . Most of congenital heart diseases are diagnosed through non-invasive methods and are referred to surgery. Cardiac catheterization still proves significant for anatomic and hemodynamic complex lesions, though 2 .
Cardiac catheterization can be applied through arterial or venous access. Development of thrombosis at the site of vascular accesses the most frequently observed complication of cardiac catheterization in children 3 . The mechanisms and structures of catheterrelated thrombosis are different from noncatheter -related thrombosis 4 . There exist some mechanisms proposed in relation to postcatheterization thrombosis such as vasospasm, intimal damage, platelet accumulation 5 .
Thrombosis leads to mortality and morbidity in children with congenital heart diseases 6 . For this reason, prevention, early diagnosis, and treatment of thrombosis are one of the priorities in patients that received catheterization. During cardiac catheterization, some centers routinely apply heparin infusion into the artery or the vein that received catheter with pediatric patients 7 . There is little research in literature studying the effects of giving prophylactic systemic heparin during cardiac catheterization on the frequency of thrombosis in newborns 8 .
In this study, which was conducted in a Level III neonatal intensive care unit (NICU), the incidence of thrombosis and factors that influence thrombosis development were studied in newborns that received diagnostic or therapeutic catheterization through femoral artery due to cyanotic congenital heart diseases and were routinely given prophylactic systemic heparin during the procedure.
METHODS
Data collection and study design: All the newborn patients that received diagnostic or therapeutic femoral artery catheterization within 6-month period in tertiary NICU, at Turkey, were involved in the study. The patients without parental consent, and received both arterial and venous intervention during the procedure were excluded from the study. Procedures were classified as diagnostic and interventional. The patients were closely monitored in terms of vital signs and complications during catheterization. Patients were premedicated with midazolam or fentanyl infusions. Appropriate arterial sheaths and catheters varying from 4F were used for catheterization. Heparin was given in a dosage of 100 units/ kg intra-arterially through the side-arm of arterial sheath. During the catheterization, the patient's clotting status was monitored by activated clotting time. Fluoroscopy time was recorded. Skin temperature and arterial pulses of the legs and feet were recorded during and after catheterization for every patient.
All the patients were given Doppler ultrasonography (USG) within 6 hours after the catheterization by a radiologist. Following the catheterization, the patients that differed from the other patients in terms of temperature, color, pulse and capillary filling among lower extremities were considered clinically suspected arterial thrombosis. In the presence of clinically suspected arterial thrombosis 75 units/ kg heparin bolus was started and 28 units/ kg/ hour were maintained until the patients received Doppler USG. Bedside Doppler USG of lower extremity arteries and veins was performed by GE Logic E portable ultrasound following cardiac catheterization. First, luminal patency of the vessels was detected by gray-scale sonography. The location of thrombosis, flow rates and flow patterns were evaluated in patients who detected thrombosis using Doppler USG. Heparin infusion was continued in the patients that were found in Doppler USG to have thrombosis restricting the lumen in superficial and common femoral artery. Those patients who did not have clinical thrombosis signs but were found to have thrombosis in Doppler USG were started with 75 units/ kg bolus of heparin infusion, and continued with 28 units/ kg/ hour. The course of vascular thrombosis was followed through Doppler USG screenings until resolving In patients receiving heparin infusion, systemic anticoagulation was provided with low molecular weight heparin (LMWH) after second day. Blood samples according to the study were drawn prior to catheterization for complete blood count (CBC), prothrombin time (PT), activated partial thromboplastin time (aPTT), factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298 mutations analysis. aPTT and anti-factor Xa levels of the patients that received heparin treatment were followed for dose adjustment. Gestational weeks, genders, birth weights, catheterization days, type of congenital heart disease, clinic followups after catheter and their complications were all recorded. Legal permit was received from local ethics committee (on 19.06.2012 with 61 decision no), and informed consent was received from the families of the patients involved in the study.
Statistical Analysis: Statistical analyses of the data were performed using SPSS V20.0 for Windows. Shapiro Wilks test was conducted to check the distribution of the variables. In summarizing the data, normally distributed variables (parametric) were presented as mean ± SD, whereas non-normally distributed variables (nonparametric) were presented as median values. The intergroup comparison of normally distributed variables was performed with student t test, and the non-normally distributed variables with Mann-Whitney U test. Chi-square test was used for intergroup comparisons of nominal variables. When cell counts were less than expected in 2x2 contingency tables, Fisher's Exact Test was applied, whereas Pearson Chi-Square analysis was used by means of Monte Carlo Simulation in RxC contingency tables. P value less than 0.05 was considered statistically significant.
RESULTS
Totally 26 patients received diagnostic and/or therapeutic femoral artery catheterization within 6-month study period. One patient was excluded due to lack of parental consent, and 5 were excluded since they received both arterial and venous intervention during the procedure and 20 newborns that received femoral artery catheterization within 6-month period were involved in the study. The secondary mortality and major complications such as excessive bleeding requiring blood transfusion and vascular rupture were not observed due to cardiac catheterization. The fluoroscopy time was median 10,5 (8-15) min in diagnostic catheterization and median 15,5 (12-26) min in interventional catheterization (p=0,001). Eight of the cases (40%) were female, and 12 of them (60%) were male. The gestational age of the patients ranged from 31 to 40 weeks (median 39 weeks). Mean birth weight was 2996 ± 589 (1880-4000) gr. Primary diagnoses of the patients were coarctation of aorta (n=11, 55%), pulmonary atresia (n=6, 30%), aortic valve anomaly (n=2, 10%) and pulmonary stenosis (n=1, 5%). Cardiac catheterization age of the cases was postnatal median 11 (2-65) days. Fifty five % of the cases (n=11) were given heparin infusion after the procedure due to suspected thrombosis in light of clinical findings. When the patients were examined 6 hours later with femoral artery Doppler USG, 50% of them (n=10) were found to have femoral artery thrombosis. Six of the 11 patients (54.5%) who were initially given additional heparin infusion due to clinically suspected thrombosis were found to have thrombosis in Doppler USG, whereas 4 of the 9 patients 44.4 (%) who were not given heparin infusion initially were found to have femoral artery thrombosis in the Doppler USG 6 hours later. No statistically significant relationship was found between giving additional heparin on account of clinically suspected thrombosis initially, and ultrasonographic detection of thrombosis during follow-up [p>0.05, Table 1 When the patients need for ventilatory support was examined, it was observed that 8 patients 40(%) received invasive mechanical ventilation, one (5%) received non-invasive mechanical ventilation, one (5%) received freeflow oxygen treatment, whereas 10 patients did not need any ventilatory support. Ten of the patients received (50%) diuretic, 6 of them (30%) inotrope, and 6 of them (30%) prostaglandin E1 treatment prior to the procedure. No correlation was found between the development of thrombosis and the need for ventilation, and receiving diuretic, inotrope, and prostaglandin E1 treatment (p>0.05) [ Table 2 ].
When the correlation between the development of thrombosis and the reason why cardiac catheterization was conducted was examined, no significant correlation was found between diagnostic and interventional cardiac catheterization group in terms of thrombosis development; however, the rate of thrombosis was found higher in diagnostic group [Thrombosis (+): Diagnostic n=6, 60(%), Interventional n=4,(40%); Thrombosis (-): Diagnostic n=4 (40%), Interventional n=6, (60%); p=0.655].There was no significant correlation between primary diagnosis of the patients and development of thrombosis (p>0.05) [ Table 2 ].
Blood samples were drawn from all patients prior to catheterization for complete blood count, kidney function tests, protein, albumin and coagulation tests. No significant correlation was found between clinically suspected thrombosis cases and those not suspected after cardiac catheterization in terms of hemoglobin, hematocrit, thrombocyte count, blood urea nitrogen, , albumin and protein levels and PT, aPTT and INR values (p>0.05) [ Table 3 ]. Figure 2 ]. In 17 of 20 cases, blood samples were taken prior to catheterization for factor V Leiden, prothrombin G20210A and MTHFR C677T and A1298 mutations. While prothrombin mutations were found to be normal in all the cases with thrombosis, factor V Leiden mutation was heterozygote in one case (14.5%). When MTHFR mutations in cases with thrombosis were evaluated, in five cases MTHR-C677T heterozygote (55.56 %), in four cases MTHFR-A1298 heterozygote (44.44 %), and in one case MTHFR-A1298 homozygote mutation (11.11%) were detected. The relationship between the presence of thrombosis and the presence of mutation in these parameters is not statistically significant (p>0.05) [ Table 4 ]. Clinical and Doppler USG findings on thrombosis recovered in all the patients who received heparin treatment due to thrombosis. The patients were discharged from the hospital after the administration of systemic anticoagulant therapy with LMWH treatment. No tissue and function loss was observed in the extremities of the patients none of the patients were given thrombolytic therapy for the treatment of thrombosis.
DISCUSSION
The technique of percutaneous insertion of catheters, which was developed by Seldinger in 1953 9 was widely used in children in the following years. One major complication of cardiac catheterization in infants and children is the arterial thrombosis. As stated in the literature, the ratio of incidence of femoral venous thrombosis after cardiac catheterization is 0-20% for infants and children, and the ratio of incidence of femoral arterial thrombosis is 0.8-40% [10] [11] [12] [13] [14] [15] [16] . In another study, the ratio of incidence of venous thrombosis in cyanotic congenital heart diseases in infants younger than 6 months was found to be 50%, while the ratio of incidence of arterial thrombosis was 70% 17 . The results of another study show that incidence of femoral arterial thrombosis is 32% in infants aged <12 months 18 . The incidence for newborns is not yet exactly known. In our study, the rate of femoral arterial thrombosis detected by Doppler ultrasonography was 50%.
Term or preterm infants with a critical illness are at the highest risk in terms of thrombosis development and serious thromboembolic complications in the pediatric population 19 . Major risk factors are fluctuations in cardiac output, congenital heart diseases, inflammation, disseminated intravascular coagulation (DIC), liver dysfunction, and the application of central arterial or venous catheter. As a result of polycythemia and hyper viscosity, developing secondary to the cyanotic congenital heart diseases, blood flow slows down and then thrombosis occurs 19 .The increase in surgical interventions and transcatheter methods leads to an increase in thromboembolism in newborns 4 . The high frequency of arterial thrombosis in our study may be associated with the presence of patients who have congenital heart disease and who received catheterization.
In this study, high thrombosis rate may be associated with the study group consisting of newborns and with the use of Doppler USG for the diagnosis of thrombosis. Brotschi et al. found the incidence of arterial thrombosis after cardiac catheterization as 32% in infants when they confirmed the diagnosis of thrombosis with Doppler USG 18 .Most studies have only used clinical assessment for the detection of cardiac catheterization related thrombosis and the true incidence of thrombosis is unknown. Therefore, studies using objective screening by ultrasound are needed 20 .In this study, data suggest that clinical assessment for the diagnosis of thrombosis may be misleading.
Prophylactic heparin treatment is a general approach used during cardiac catheterization in children. However, there is not a universallyaccepted heparin dose used to prevent arterial thrombosis.
Few studies compare unfractionated heparin (UFH) protocols within the dosage range of 50 to 150 U/ kg [10] [11] [12] [13] . The current suggestion is to use 100-150 units per kg body weight bolus UFH and an additional bolus dose during the treatment 21 . In HEARTCAT study, the superiority of 100 U/kg UFH dose over 50 U/kg dose could not be shown. In ınfants, effects of UFH in plasma were lower than in older children. This age dependency effect of UFH was more noticeable at lower UFH dose 22 . The incidence of thrombosis despite the use of 100 U/kg UFH in all the cases in our study may be associated with other factors that may be influential in the development of thrombosis.
Heller and colleagues recommend screening of resistance to activated protein C (APC-R), protein C, protein S, and antithrombin activity, concentration of clot table fibrinogen, plasminogen activity, activities of coagulation factors VIIIC and XII, Lp(a), histidine-rich glycoprotein, heparin cofactor II, antiphospholipid antibodies, lupus anticoagulants as well as fasting homocysteine concentrations in newborns who developed thromboembolism. In addition, there are studies which suggest performing DNA-based assays (i.e., factor V G1691A mutation, factor II G20210A variant and MTHFR C677T genotype) 23, 24 . The presence of some thrombophilia mutations did not shown any effect on the development of thrombosis in this study. This result suggests that environmental factors are particularly effective in acute occlusive situations like arterial thrombosis.
There are several studies showing that children with congenital heart disease have various coagulation disorders 25 . Coagulation factor deficiencies, low platelet, prothrombin time and antithrombin 3 activities were detected in these patients 26 . When the clinical and laboratory parameters which were obtained from our study and which are influential on the development of thrombosis are evaluated, it is seen that the only significant factor is the INR levels. It was found that the cases with thrombosis had lower levels of INR compared to those without thrombosis, and the cut-off value for INR level in detecting thrombosis was found to be 1.21. In patients with an INR greater than 1.2, the lower incidence of thrombosis may be due to the more pronounced anticoagulant effect of heparin on these patients. We can speculate according to this result that premedication with effective drugs on INR levels before cardiac catheterization reduces the incidence of thrombosis.
The limitations of our study are low number of patients, heterogenic distribution of gestational ages and birth weights of cases. And also evaluation of clinical findings of thrombosis may show individual differences. The strength of this study is that all patients were closely followed with clinically, laboratory and Doppler USG until discharge.
CONCLUSION
In recent years, there have been significant improvements in the diagnosis and treatment of congenital heart diseases. Among these recent approaches, preventing the complications resulting from catheterization is one key objective. It is believed that Doppler USG which will be applied on thrombosis before the appearance of secondary clinical findings is important in the early detection and treatment of thrombosis. To prevent thrombotic incidences, new studies must be conducted to explore the heparin bolus doses used during catheterization in newborns. To this end, studies with a large number of cases are required.
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